tetano
Editor, Senior Moderator
Crit Care. 2017 Apr 19;21(1):97. doi: 10.1186/s13054-017-1672-7.
[h=1]Plasma metabolomics for the diagnosis and prognosis of H1N1 influenza pneumonia.[/h] Banoei MM[SUP]1[/SUP], Vogel HJ[SUP]2[/SUP], Weljie AM[SUP]2,[/SUP][SUP]3[/SUP], Kumar A[SUP]4[/SUP], Yende S[SUP]5,[/SUP][SUP]6[/SUP], Angus DC[SUP]5,[/SUP][SUP]6[/SUP], Winston BW[SUP]7,[/SUP][SUP]8,[/SUP][SUP]9[/SUP]; Canadian Critical Care Translational Biology Group (CCCTBG).
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Metabolomics is a tool that has been used for the diagnosis and prognosis of specific diseases. The purpose of this study was to examine if metabolomics could be used as a potential diagnostic and prognostic tool for H1N1 pneumonia. Our hypothesis was that metabolomics can potentially be used early for the diagnosis and prognosis of H1N1 influenza pneumonia.
[h=4]METHODS:[/h] [SUP]1[/SUP]H nuclear magnetic resonance spectroscopy and gas chromatography-mass spectrometry were used to profile the metabolome in 42 patients with H1N1 pneumonia, 31 ventilated control subjects in the intensive care unit (ICU), and 30 culture-positive plasma samples from patients with bacterial community-acquired pneumonia drawn within the first 24 h of hospital admission for diagnosis and prognosis of disease.
[h=4]RESULTS:[/h] We found that plasma-based metabolomics from samples taken within 24 h of hospital admission can be used to discriminate H1N1 pneumonia from bacterial pneumonia and nonsurvivors from survivors of H1N1 pneumonia. Moreover, metabolomics is a highly sensitive and specific tool for the 90-day prognosis of mortality in H1N1 pneumonia.
[h=4]CONCLUSIONS:[/h] This study demonstrates that H1N1 pneumonia can create a quite different plasma metabolic profile from bacterial culture-positive pneumonia and ventilated control subjects in the ICU on the basis of plasma samples taken within 24 h of hospital/ICU admission, early in the course of disease.
[h=4]KEYWORDS:[/h] Biomarkers; GC-MS; H1N1 pneumonia; Metabolomics; NMR
PMID: 28424077 PMCID: PMC5397800 DOI: 10.1186/s13054-017-1672-7
Free PMC Article
[h=1]Plasma metabolomics for the diagnosis and prognosis of H1N1 influenza pneumonia.[/h] Banoei MM[SUP]1[/SUP], Vogel HJ[SUP]2[/SUP], Weljie AM[SUP]2,[/SUP][SUP]3[/SUP], Kumar A[SUP]4[/SUP], Yende S[SUP]5,[/SUP][SUP]6[/SUP], Angus DC[SUP]5,[/SUP][SUP]6[/SUP], Winston BW[SUP]7,[/SUP][SUP]8,[/SUP][SUP]9[/SUP]; Canadian Critical Care Translational Biology Group (CCCTBG).
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Metabolomics is a tool that has been used for the diagnosis and prognosis of specific diseases. The purpose of this study was to examine if metabolomics could be used as a potential diagnostic and prognostic tool for H1N1 pneumonia. Our hypothesis was that metabolomics can potentially be used early for the diagnosis and prognosis of H1N1 influenza pneumonia.
[h=4]METHODS:[/h] [SUP]1[/SUP]H nuclear magnetic resonance spectroscopy and gas chromatography-mass spectrometry were used to profile the metabolome in 42 patients with H1N1 pneumonia, 31 ventilated control subjects in the intensive care unit (ICU), and 30 culture-positive plasma samples from patients with bacterial community-acquired pneumonia drawn within the first 24 h of hospital admission for diagnosis and prognosis of disease.
[h=4]RESULTS:[/h] We found that plasma-based metabolomics from samples taken within 24 h of hospital admission can be used to discriminate H1N1 pneumonia from bacterial pneumonia and nonsurvivors from survivors of H1N1 pneumonia. Moreover, metabolomics is a highly sensitive and specific tool for the 90-day prognosis of mortality in H1N1 pneumonia.
[h=4]CONCLUSIONS:[/h] This study demonstrates that H1N1 pneumonia can create a quite different plasma metabolic profile from bacterial culture-positive pneumonia and ventilated control subjects in the ICU on the basis of plasma samples taken within 24 h of hospital/ICU admission, early in the course of disease.
[h=4]KEYWORDS:[/h] Biomarkers; GC-MS; H1N1 pneumonia; Metabolomics; NMR
PMID: 28424077 PMCID: PMC5397800 DOI: 10.1186/s13054-017-1672-7
Free PMC Article